🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Hong, Curran, and Naing assess the safety & preliminary efficacy of the combination of #lefitolimod and #ipilimumab in patients with advanced solid tumors doi.org/10.36401/JIPO-… #immunotherapy #checkpointinhibitor #phase1trial David S. Hong MD Aung Naing Innovative Oncology Network

Suarez-Almazor et al. interview expert rheumatologists to determine best practices and the potential deleterious effects of various agents on tumor progression doi.org/10.36401/JIPO-… #adverseevent #ICItherapy #ICI #arthritis #JIPO Innovative Oncology Network

Falchook et al. summarize past and current CDK2 inhibitors in clinical trials in this #JIPO review doi.org/10.36401/JIPO-… #CDK2 #clinicaltrial #JIPO Innovative Oncology Network

Kumar et al. evaluate the usefulness of comprehensive genomic profiling in clinical decision-making in oncology doi.org/10.36401/JIPO-… #advancedcancer #genomicprofiling #precisiononcology #JIPO Innovative Oncology Network

In recent research article, Patel et al. investigate a Phase 1B clinical trial combining Selinexor (KPT-330) & immune checkpoint inhibitor to treat uveal melanoma doi.org/10.36401/JIPO-… #clinicaltrial #phase1 #uvealmelanoma #JIPO Mohamed A Gouda #Selinexor Innovative Oncology Network

#AACR25 #JIPO Editor in Chief and Editorial Fellow Carlos Torrado Aung Naing

⭐️Exhilarating discussions with the amazing Dr. Patrick Hwu Moffitt Cancer Center on his new podcast #Immunoverse & Dr. Steven Rosenberg Chief of the Surgery Branch National Cancer Institute. Fantastic to meet my great colleague Aung Naing JIPO Editors EIC MD Anderson Cancer Center AACR #AACR25 OncoAlert

Vargas et al. explores incidence of acute and chronic GVHD and to analyze factors associated with the its development during the first year after transplantation doi.org/10.36401/JIPO-… #graftversushost #stemcell #JIPO #GVHD #transplant Innovative Oncology Network

Naing et al. research the "Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma" in a phase 1 study doi.org/10.36401/JIPO-… #ICI #programmedcelldeath #cholangiocarcinoma #JIPO Innovative Oncology Network

The OncoAlert🚨ROUND UP Now Out‼️ Covering May 15-22, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… ⭐️Discussing ✅Systemic tx for HR+/HER2- early stage and metastatic #BreastCancer ✅Hypofractionated, Dose-Escalated Radiation Versus Conventionally

LAST CALL! Apply for a 1-year Editorial Fellowship with #JIPO! Applications are open through June 2, 2025. meridian.allenpress.com/innovationsjou… Innovations Journals #fellowship #medicalpublishing #peerreview

Hong, Curran, and Naing assess the safety & preliminary efficacy of the combination of #lefitolimod and #ipilimumab in patients with advanced solid tumors doi.org/10.36401/JIPO-… #immunotherapy #checkpointinhibitor #phase1trial #JIPO David S. Hong MD Aung Naing

New #JIPO case report by Demiray et al. "Exceptional response in a patient with mRCC through precision-guided treatment involving immunotherapy rechallenge with temsirolimus and bevacizumab" doi.org/10.36401/JIPO-… #immunotherapy

Last call! #JIPO invites manuscript submissions highlighting regional advances and challenges in #precisiononcology. Deadilne extended to July 1! meridian.allenpress.com/DocumentLibrar… Innovations Journals Innovative Oncology Network

Early findings from a first-in-human trial of VLS-1488, an oral KIF18A inhibitor, show promising anti-tumor activity in heavily treated ovarian cancer. No dose-limiting toxicities were observed. Presented by Dr. Ecaterina Dumbrava at #ASCO25. #EndCancer